Table 4.
Serum iPTH and alkaline phosphatase: values at baseline, week 9 and 25 and changes from baseline (FAS, N = 244)
| Parameter | CaMg |
Sevelamer-HCl |
P-value | ||
|---|---|---|---|---|---|
| N | (Mean ± SD) | N | (Mean ± SD) | ||
| Serum iPTH (pg/mL) | |||||
| Baseline | 119 | 450.84 ± 273.494 | 118 | 438.97 ± 238.112 | |
| Week 9 | 118 | 361.25 ± 278.526 | 112 | 357.71 ± 201.909 | |
| Change at Week 9 | 115 | −85.28 ± 195.308 | 108 | −72.69 ± 154.429 | 0.6059 |
| Week 25 | 118 | 337.20 ± 266.357 | 112 | 384.67 ± 226.349 | |
| Change at Week 25 | 115 | −109.24 ± 229.903 | 108 | −43.98 ± 171.438 | |
| Treatment difference (LS-means) [confidence interval] | −64.4773 [−112.3087, −16.6459] | 0.0085 | |||
| Significant covariate factor | |||||
| Intake of calcimimetics | 0.0211 | ||||
| Serum alkaline phosphatase (U/L) | |||||
| Baseline | 122 | 100.39 ± 49.689 | 122 | 93.00 ± 38.384 | |
| Week 9 | 116 | 108.44 ± 52.237 | 104 | 120.42 ± 52.675 | |
| Change at Week 9 | 116 | 8.85 ± 23.523 | 104 | 25.32 ± 27.006 | <0.0001 |
| Week 25 | 116 | 106.84 ± 53.803 | 105 | 125.93 ± 53.479 | |
| Change at Week 25 | 116 | 7.26 ± 32.438 | 105 | 30.90 ± 34.101 | |
| Treatment difference (LS-means) [confidence interval] | −24.0067 [−32.8963, −15.1175] | <0.0001 | |||